



## ASX Announcement

23 January 2025

### Hydrix signs key international \$2.8m contract with European Medtech

**Hydrix Limited (Hydrix or the Company)** (ASX: **HYD**) is pleased to announce that its wholly owned subsidiary, Hydrix Services, has entered into a **\$2.8m** contract extension with leading European medical device company Paul Hartmann AG (**Hartmann**).

The contract extension represents a further stage of works that Hydrix Services will undertake for Hartmann, as part of a multi-stage product development program. Hydrix anticipates that the stage of works will be completed, and all **\$2.8m** of revenue will be recognised, by the end of September 2025, **adding to the \$3.7m** cumulative revenue from previous contract stages.

#### Hydrix International expansion strategy is succeeding

Alan Morris, Group Marketing Director, commented:

*“Winning this project stage highlights our dedication to excellence and innovation, strengthens our growing reputation in international markets, and advances our strategy of pursuing global opportunities.”*

Ends --

This announcement is authorised for release by the Board of Directors of Hydrix Limited.

For more information, please contact:

**Company Enquiries:** Gavin Coote - Executive Chairman  
[info@hydrix.com](mailto:info@hydrix.com)  
+61 3 9550 8100

**Corporate Advisory** Matthew Baker - Corporate Adviser, Blue Ocean Equities  
[MatthewBaker@boeq.com.au](mailto:MatthewBaker@boeq.com.au)  
+61 418 830 064

**Media Enquires:** Rod North - Managing Director, Bourse Communications  
[rod@boursecommunications.com.au](mailto:rod@boursecommunications.com.au)  
+61 3 9510 8309



## About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix's purpose is to enhance the health, safety, and well-being of a billion lives. The company leverages its powerful product innovation capability across three business segments: **Services**: design, engineer and deliver world first products and innovation; **Ventures**: invest in high potential MedTech clients; and **Medical**: distribute disruptive cardiovascular products.

For personal use only